Expertise in
22
conditions

Dr. Suneet K. Grewal

Rheumatology
Office
3737 Lone Tree Way Ste E, 
Antioch, CA 
Accepting New Patients
Offers Telehealth
Referral required
Before you request
Expertise in
22
conditions
Office
3737 Lone Tree Way Ste E, 
Antioch, CA 

Overview

Suneet Grewal is a Rheumatologist practicing medicine in Antioch, California.

Dr. Grewal is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Rheumatoid Arthritis (RA), Sjogren Syndrome, Non-Radiographic Axial Spondyloarthritis (nr-axSpA), and Fibromyalgia.

She is actively involved in clinical research, co-authoring 2 peer reviewed articles and participating in 7 clinical trials. Dr. Grewal is currently accepting new patients.

Specialties

Rheumatology

Licenses

Internal Medicine in CA

Hospital Affiliations

Eden Medical Center

Languages Spoken

English
Hindi
Punjabi

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
California Health And Wellness
  • MANAGED MEDICAID PLAN
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Contra Costa Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
Sutter Health
  • HMO
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 19 Less Insurance Carriers -

Locations

Office
3737 Lone Tree Way Ste E, Antioch, CA 94509

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients With Rheumatoid Arthritis
Enrollment Status: Completed
Publish Date: June 24, 2026
Intervention Type: Drug
Study Drugs: Baricitinib, TNF Inhibitor
Study Phase: Phase 4
A Phase 4, Open-Label, Multicenter, Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Trial of Intravenous KRYSTEXXA® (Pegloticase) Administered Every 4 Weeks With Co-Administration of Weekly Doses of Methotrexate in Patients With Uncontrolled Refractory Gout (FORWARD Open-Label [OL] Trial)
A Phase 4, Open-Label, Multicenter, Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Trial of Intravenous KRYSTEXXA® (Pegloticase) Administered Every 4 Weeks With Co-Administration of Weekly Doses of Methotrexate in Patients With Uncontrolled Refractory Gout (FORWARD Open-Label [OL] Trial)
Enrollment Status: Completed
Publish Date: May 19, 2026
Intervention Type: Biological, Drug
Study Drugs: Pegloticase, Methotrexate
Study Phase: Phase 4
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Tofacitinib in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic DMARDs or Biologic DMARDs
Enrollment Status: Terminated
Publish Date: November 30, 2023
Intervention Type: Drug, Biological
Study Drugs: Otilimab, Tofacitinib, csDMARDs
Study Phase: Phase 3
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
A 24-week, Phase 3, Multicentre, Randomised, Double-blind, Efficacy and Safety Study, Comparing GSK3196165 With Placebo and With Sarilumab, in Combination With Conventional Synthetic DMARDs, in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological DMARDs and/or Janus Kinase Inhibitors
Enrollment Status: Completed
Publish Date: July 17, 2023
Intervention Type: Drug, Biological
Study Drugs: GSK3196165, Sarilumab, csDMARDs
Study Phase: Phase 3
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects With SLE
Enrollment Status: Terminated
Publish Date: April 12, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase IIb, Randomized, Double-blind Study in Subjects With Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared With Placebo in Subjects With an Inadequate Response to Methotrexate
A Phase IIb, Randomized, Double-blind Study in Subjects With Rheumatoid Arthritis Evaluating the Safety and Efficacy of Evobrutinib Compared With Placebo in Subjects With an Inadequate Response to Methotrexate
Enrollment Status: Completed
Publish Date: September 28, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

2 Total Publications

A Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12-Month Findings.
A Randomized, Double-Blind, Placebo-Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12-Month Findings.
Journal: ACR open rheumatology
Published: March 13, 2023
Similar Doctors
Expertise in
2
conditions
Dr. David Wofsy
Rheumatology
Expertise in
2
conditions
Dr. David Wofsy
Rheumatology
Referral may be required
Before you request

Univ Of California Home Care Serv

400 Parnassus Ave, 
San Francisco, CA 
 (38.7 miles away)
415-502-2279
Languages Spoken:
English
See accepted insurances
Accepting New Patients

David Wofsy is a Rheumatologist practicing medicine in San Francisco, California. Dr. Wofsy is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Lupus Nephritis and Systemic Lupus Erythematosus (SLE). Dr. Wofsy is currently accepting new patients.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required
Before you request

Ankylosing Spondylitis Clinic

400 Parnassus Ave., Floor B1, 
San Francisco, CA 
 (38.7 miles away)
415-353-2497
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Dr. Lianne Gensler is a rheumatologist and serves as director of the UCSF Ankylosing Spondylitis Clinic, which is dedicated to care for this inflammatory disease. Gensler's primary research interest is the disease progression of axial spondyloarthritis (a category that includes ankylosing spondylitis). Her research also seeks to identify predictors of osteoporosis development in patients with systemic lupus erythematosus. Gensler earned her medical degree at the University of California, Irvine. She completed an internal medicine residency, chief residency and rheumatology fellowship at UCSF, and subsequently joined the medical staff in the rheumatology program. Dr. Gensler is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Ankylosing Spondylitis, Axial Spondyloarthritis (AxSpA), Arthritis, and Rheumatoid Vasculitis. Dr. Gensler is board certified in American Board Of Internal Medicine/Rheumatology, Rheumatology. Dr. Gensler is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required
Before you request

Palo Alto VA Medical Center

3801 Miranda Ave, 
Palo Alto, CA 
 (44.6 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Lorinda Chung is a Rheumatologist practicing medicine in Palo Alto, California. Dr. Chung is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Scleroderma, Systemic Sclerosis (SSc), Dermatomyositis, and Polymyositis. Dr. Chung is currently accepting new patients.

Frequently Asked Questions about Dr. Suneet K. Grewal

How do I make an appointment with Dr. Suneet K. Grewal?

You can book an appointment with Dr. Suneet K. Grewal by calling their office at 510-357-1303. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Suneet K. Grewal a top-rated expert for Rheumatoid Arthritis (RA)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Suneet K. Grewal is classified as an Distinguished expert for Rheumatoid Arthritis (RA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Suneet K. Grewal specialize in?

While Dr. Suneet K. Grewal is a Rheumatology, they have specific expertise in Rheumatoid Arthritis (RA), Sjogren Syndrome, and Non-Radiographic Axial Spondyloarthritis (nr-axSpA). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Rheumatology.

Does Dr. Suneet K. Grewal participate in research or clinical trials?

Yes. Dr. Suneet K. Grewal has published 2 articles and abstracts on conditions like Rheumatoid Arthritis (RA). You can view a list of Dr. Suneet K. Grewal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Suneet K. Grewal accept my insurance?

Dr. Suneet K. Grewal accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 510-357-1303 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Grewal's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 37 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile